ERASCA INC. DL -,0001 Aktie Logo
US29479A1088
A3CU1G
ERAS

ERASCA INC. DL -,0001 Aktie

A carregar cotações...

Previsão

O preço-alvo médio dos analistas é € 18,85 (+45,34%). A mediana é € 19,16 (+47,73%).

Comprar
  9
Manter
  2
Vender
  0

Discussões na comunidade

Ainda não há nenhuma discussão sobre este ativo.

Iniciar discussão

  • Erasca places shares for $550 million at $17.50 per share

    Erasca placed 31,428,572 common shares at $17.50 per share and expects gross proceeds of about $550 million. The lead managers were granted a 30-day option to purchase up to 4,714,285 additional shares at the offering price. Net proceeds are intended to finance research and development, ongoing development programs and working capital; the closing of the transaction is expected on July 15, 2026. » Mais em de.investing.com


  • Erasca plans $500 million capital raise despite positive phase‑1 data

    Erasca announced a guaranteed public placement of common stock totaling $500 million plus a 30‑day option for $75 million; the proceeds are intended for R&D and working capital, which triggered shareholder dilution concerns and sent the stock down about 3.1% in after‑hours trading. At the same time the company released updated phase‑1 data for ERAS‑0015: an unconfirmed overall response rate of 57% at eight weeks in patients with ductal pancreatic cancer and KRAS‑G12X mutation; recommended dose 32 mg once daily, with six of seven patients remaining on treatment. Goldman Sachs initiated coverage with an "Early‑Stage Biotech" rating and views Erasca as a leader in RAS targeting behind Revolution Medicines; ongoing litigation and a weak market backdrop heighten near‑term risks. » Mais em de.investing.com


  • Erasca plans $500 million share offering to finance research

    Erasca intends to issue common shares in a syndicated public offering totaling $500 million and to grant the bookrunners a 30-day option to purchase additional shares worth up to $75 million. The securities will be offered under an S-3 shelf registration; J.P. Morgan, Morgan Stanley, Jefferies and Evercore ISI are leading the syndicate. Net proceeds and existing cash will be used to fund research and development, working capital and general corporate purposes. The announcement follows a strong share rally and a market capitalization of about $5.57 billion; the stock is rated overvalued in the analysis and the company remains unprofitable (EPS -$0.96). » Mais em de.investing.com


  • Erasca reports positive phase 1 data for RAS inhibitor ERAS‑0015

    Erasca released preliminary phase 1 results for the oral pan‑RAS inhibitor ERAS‑0015: in the AURORAS‑1 study, seven PDAC patients with KRAS G12X showed an unconfirmed overall response rate of 57% at eight weeks. The recommended dose for the expansion phase is 32 mg once daily; treatment‑related adverse events were mostly mild, with no dose‑limiting toxicities or treatment‑related discontinuations. Combination data with panitumumab showed no DLTs in the 16 mg cohort; Erasca plans phase 3 trials in PDAC and RAS‑mutant NSCLC for 2027/2028 and expects further data in H1 2027. The positive results contributed to a strong share price increase and a market capitalization of about $5.57 billion. » Mais em de.investing.com


  • Erasca bets on drug candidate ERAS‑0015 despite earlier setbacks

    Erasca is a development-only precision oncology company without any revenue base, whose future depends on the success of its flagship candidate ERAS‑0015. After a death in an early trial and a patent dispute, the stock suffered significant losses in spring 2026, but market value still stood at over USD 5.7 billion in July 2026. The business model remains based on venture capital and partnerships, while the clinical progress of ERAS‑0015 will determine further growth. » Mais em finanzen.net

Dados financeiros da empresa

No último trimestre, ERASCA INC. DL -,0001 Aktie registou receitas de € 0 e um ganho líquido de -€ 45,32 mi
(EUR) setembro de 2026
YoY
Receitas 0 -
Ganho bruto 0 -
Ganho líquido -45,32 mi 73,73%
EBITDA -44,69 mi 75,65%

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 4,45 bi
Número de ações
350,96 mi
Máximo/mínimo de 52 semanas
€ 22,15 - € 2,51
Dividendos Não
Beta
0,65
PER (PE Ratio)
-14,03
PEG (PEG Ratio)
0,13
P/VC (PB Ratio)
5,22
P/V (PS Ratio)
0,00

Perfil da empresa

A Erasca, Inc., uma empresa biofarmacêutica em fase clínica, dedica-se à descoberta, desenvolvimento e comercialização de terapêuticas para doentes com cancros impulsionados pela via RAS/MAPK. Os principais candidatos da empresa incluem o ERAS-007, um inibidor oral de ERK1/2 para o tratamento do cancro do pulmão de não pequenas células, do cancro colorretal e da leucemia mieloide aguda; e o ERAS-601, um inibidor oral de SHP2 para doentes com tumores sólidos avançados ou metastáticos. A empresa desenvolve também o ERAS-801, um inibidor de EGFR com capacidade de penetração no sistema nervoso central, para o tratamento de doentes com glioblastoma multiforme recorrente. A empresa foi constituída em 2018 e tem sede em San Diego, Califórnia.

Nome
ERASCA INC. DL -,0001 Aktie
CEO
Jonathan E. Lim
Sede San Diego, ca
EUA
Site
Setor
Materiais básicos
Indústria
Produtos químicos
Entrada em bolsa
16/07/2021
Colaboradores 103

Símbolos de ticker

Bolsa Símbolo
NASDAQ
ERAS
🍪

Parqet  utiliza cookies. Saber mais